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There are no adequate data that evaluate the safety and eﬀectiveness of lowering triglyceride levels in very young children. The
authors report a family with two male siblings, 7 and 4 years old, aﬀected by familial hyperchylomicronemia. The oldest was
diagnosed at birth during evaluation of jaundice, and the youngest showed asymptomatic hypertriglyceridemia by 6 months of
age. Due to high triglyceride levels, Gemﬁbrozil (a ﬁbric acid derivative) was started at diagnosis. Close clinical followup and
laboratory monitoring of these children showed no side eﬀects from the drug, and the risk of acute pancreatitis was signiﬁcantly
reduced.
1.Introduction
Hyperlipidemia is an increasingly prevalent risk factor in
children, concomitant with the worldwide epidemic of
obesity [1]. Lipid disorders can occur either as a primary
event or secondary to an underlying disease. The primary
dyslipidemias are associated with overproduction and/or
impaired removal of lipoproteins. The latter defect can be
induced by an abnormality in either the lipoprotein itself
or in the lipoprotein receptor [2]. Monogenic disorders that
cause abnormal levels of plasma cholesterol and triglyc-
erides have received much attention due to their role in
metabolic dysfunction and cardiovascular disease. While
these disorders often present clinically during adulthood,
some present in the pediatric population and can have
serious consequences if misdiagnosed or untreated [3].
Hypertriglyceridemia is deﬁned as having plasma triglyc-
eride above the 95th percentile for age and sex [2]. It is
a rare disorder in childhood. According to the National
CholesterolEducationProgram(NCEP),normaltriglyceride
level is <150mg/dL (<1.7mmol/L) [4]. Primary hyper-
triglyceridemia is the result of various genetic defects leading
to disordered triglyceride metabolism. Secondary causes are
acquired and may include a high-fat diet, obesity, diabetes,
hypothyroidism, and certain medications (e.g., estrogen and
tamoxifen) [4].
Familial chylomicronemia syndrome (FCS) is disorder
of lipoprotein metabolism due to familial lipoprotein lipase
(LPL) or apolipoprotein C-II deﬁciency (Apo C-II) or the
presenceofinhibitorstolipoproteinlipase[5].Itisaveryrare
syndrome with prevalence of approximately 1 in 1 million
for homozygotes. It is relatively common for heterozygotes,
approximately 1 in 500 [6]. The disease has been described
in all races. To date, several hundred patients with LPL
deﬁciency have been described [7–9].
FCS is the most dramatic example of severe hyper-
triglyceridemia. Almost all patients with fasting triglyceride
levels in excess of 1000mg/dl (11.36mmol/L) have FCS
[4]. It manifests as eruptive xanthomas, acute pancreatitis,
hepatomegaly, splenomegaly, foam cell inﬁltration of bone
marrow, and lipemia retinalis. These patients usually have
lipemic plasma due to marked elevation of triglyceride and
chylomicron levels [10].
Several mutations in the LPL gene located on chromo-
some 8p22 have been identiﬁed with familial LPL deﬁciency
[11]. More than 50 missense and nonsense mutations have
been identiﬁed. The majority of mutations are located on
exons 3, 5, and 6 which are responsible for the catalytic2 Case Reports in Medicine
Table 1: Results of Lipid proﬁle, liver function, and complete blood count for AA at 2 months, 18 months, 2 years, and 4 years.
Case 1 Normal range
2 months 18 months 2 years 4 years
Lipid CHO (mmol/L) 2.58 1.7 3.99 4.4 <4.40
TGD (mmol/L) 5.26 >25 11.32 >10.06 <1.70
HDL (mmol/L) 0.6 0.6 0.48 0.37 <1.55
LDL (mmol/L) 1.04 0.5 0.87 0.7 <2.260
VLDL NS 4.45 NS NS
LFT ALK (u/L) 232 335 369 343 <500
AST (u/L) 39 45 60→29 33 3–34
ALT (u/L) 21 18 14 15 5–55
GGT (u/L) 1 2 9 7 12–64
CBC Hb (g/dL) 10.5 12.4 11.0–14.5
Hct (l/L) 0.287 0.287 0.340–.440
Figure 1: Refrigerated lipemic sample.
coding region of the gene [6]. Apo C-II gene mutation
has also been identiﬁed [12]. Other extremely rare genetic
disorders can present with chylomicronemia with severe
hypertriglyceridemia. Examples of these are familial apoAV
deﬁciency, familial lipase maturation factor 1 (LMF1) deﬁ-
ciency, and familial GPIHDLBP1 deﬁciency [13].
We report a family with two siblings aﬀected by FCS. We
describe the clinical features, course of the disease and its
management, and review the literature.
2.CaseOne
AA is a 7-year-old boy delivered by spontaneous vaginal
deliveryinaprimaryhealthcarecenterwithuneventfulpreg-
nancy.Whilebeinginvestigatedforjaundiceinthe2nddayof
life, he was discovered to have high cholesterol >500mg/dL
(>5.68mmol/L, normal <4.40mmol/L), low hemoglobin
(HB) 6.7g/dL (normal range 13.6–19.6g/dL), and normal
serum bilirubin and platelet count. The lipid proﬁle was
repeated. The laboratory work showed a very thick blood
sample that was hyperlipidemic (Figure 1). The repeated
lipid proﬁle showed (laboratory method used: AEROSET
system and ARCHITECT c8000 system) serum choles-
terol 7.4mmol/L (normal <4.40mmol/L), high density
lipoprotein (HDL) 1.10mmol/L (normal >1.55mmol/L),
and triglyceride (TG) 80mmol/L (normal <1.70mmol/L).
Based on this very abnormal lipid proﬁle compared to his
age, the primary healthcare facility started him on lipid
lowering agents: gemﬁbrozil (lipoid) 300mg twice a day and
pravastatin 10mg once a day. AA was referred to a tertiary
hospital at age 60 days.
Further history revealed that AA is the ﬁrst child born
to ﬁrst-degree consanguineous parents with positive family
history of hyperlipidemia, maternal side in old age (father
and aunt). There is no history of sudden death, premature
cardiovasculardisease,orrecurrentpancreatitisinthefamily.
Both parents had no history of hyperlipidemia.
Examinationrevealedanactivechildwithnodysmorphic
features or skin lesions. Abdominal examination revealed
hepatomegaly. Cardiovascular examination was normal, as
well as blood pressure. He was referred to the ophthalmol-
ogist for retinal examination which showed lipemia retinalis.
Laboratory investigation showed normal low-density
lipoprotein (LDL), high-density lipoprotein (HDL), liver
enzymes, baseline echocardiogram (ECHO), electrocardio-
gram(ECG),andultrasoundspleen.Ultrasoundofabdomen
conﬁrmed hepatomegaly. Blood investigations are summa-
rized in (Table 1).
Based on this incidentally discovered hyperlipidemia
with very high TG and low to normal VLDL at such
a young age, laboratory investigations indicate that this
child probably has FCS. He was continued on Gemiﬁrazil
(lipoid) 300mg twice a day. Pravastatin was stopped as no
evidence supports its use in treating hypertriglyceridemia.
The parents were referred to a dietitian and a low-fat diet
was recommended, including mixing food with olive oil and
giving skimmed dairy products as he is growing. Followup is
ongoing.Case Reports in Medicine 3
Table 2: Results of the Lipid proﬁle, liver function, and complete blood count for SA at 1 month, 6 months, 1 year, 2 years, and 4 years.
Case 2 Normal range
1 month 6 months 1 year 2 years 4 years
Lipid CHO (mmol/L) 2.32 7.09 5.27 4.78 3.65 <4.40
TGD (mmol/L) 5.92 10.56 12.37 >16.05 >16.05 <1.70
HDL (mmol/L) 0.47 0.34 0.47 0.4 0.46 <1.55
LDL (mmol/L) <1 1.03 0.61 0.66 <2.260
VLDL
LFT ALK(u/L) 189 283 169 379 <500
AST(u/L) 49 54 55 39
ALT(u/L) 21 18 38 24
GGT(u/L) 99 17 36
CBC Hb(g/dL) 18.7 13.6 12.2 10.9 11.0–14.5
Hct(l/L) 0.549 0.39 0.339 0.334 0.340–.440
AA was admitted twice at the age of 6 months and
again at the age of 2 years. Both times he had vomiting and
loose stool. He was diagnosed with acute gastroenteritis and
was managed accordingly. Acute pancreatitis was suspected
but could not be proved. He had no further attacks of
abdominalpainoradmissionsandwasregularlyfollowedup.
Eruptive xanthomata developed on the elbows and ear lobes
at the age of four years, which was transient and resolved
spontaneously. Lipid proﬁle, liver function, and complete
blood count were closely monitored (Table 1).
3.CaseTwo
SA is a 4-year-old boy. He was referred at age 16 days
because of the positive family history of hypertriglyc-
eridemia. He had full-term, spontaneous vaginal delivery
with uneventful pregnancy. Examination revealed an active,
but not dysmorphic baby. No skin manifestation. Abdomen
showed no hepatosplenomegaly. Examination of the cardio-
vascular system was normal, including blood pressure. Eye
examination was normal. Baseline ultrasound of abdomen,
ECG, and Echo were normal. Laboratory investigations
revealed TG 5.92mmol/L, high (normal <1.70mmol/L),
cholesterol 2.32mmol/L normal (normal <4.40mmol/L),
HDL 0.47mmol/L (normal >1.55mmol/L), LDL <1mmol/L
(normal <2.26mmol/L), and HB 18.7g/dL (13.6–19.6g/dL).
He was given dietary advice but no lipid-lowering drug was
started. He was observed with close follow up.
Six months later, TG was signiﬁcantly raised: TG
10.56mmol/L (929mg/dL), cholesterol 7.09mmol/L, HDL
0.34mmol/L, and LDL 1.03mmol/L. Due to the positive
family history and abnormal laboratory ﬁndings, he was
started on Gemiﬁrazil (lipoid) 300mg twice a day. Liver
enzymes were normal prior to commencing medications.
SA was also referred to a dietitian for low-fat milk
a n dd i e t a r ya d v i c e .O nf o l l o wu ph ew a sn o t i c e dt oh a v e
hepatomegaly and eruptive xanthomas on the elbows, which
was transient and resolved spontaneously. There was no his-
tory of abdominal pain or hospital admission for suspected
pancreatitis. The eye examination showed no evidence of
lipemia retinalis. Lipid proﬁle, complete blood count, and
liver enzymes were continuously monitored (Table 2).
4. Discussion
FCS usually manifests in childhood, but 25% of cases
manifested during infancy [14] and are rarely manifest in the
newbornperiod,asincase1(AA),whowasdiagnosedinday
two of life. In India, several cases have been reported in very
youngchildrenagedbetween20and60days.Somepresented
with features of sepsis with systemic complications and acute
renal failure with complete recovery [15]. As mentioned
above, the genetic diagnosis for FCS is available but only for
limited laboratories. For our cases, the diagnosis was clinical
and genetic testing was not available.
FCS is characterized by severe hypertriglyceridemia with
episodes of abdominal pain, recurrent acute pancreatitis,
eruptive cutaneous xanthomata, hepatosplenomegaly, and
lipemia retinalis. However, evidence suggests that presenta-
tion during infancy can be heterogeneous and may include
other signs such as pallor, anemia, jaundice, irritability,
and diarrhea. These manifestations are variable in the time
and severity of presentation [3]. One study conducted in
Quebec, Canada, in which LPL deﬁciency was demonstrated
in 16 infants who presented with heterogeneous features,
irritability, pallor, anemia,and gastrointestinal bleed, while
others presented with splenomegaly and positive family
history. This is also demonstrated in case one, he was
accidently found to have severe hypertiglyceridemia when he
was evaluated for pallor and jaundice [16].
This syndrome is autosomal recessive, and a positive
family history (e.g., a child in a family) will necessitate
screening of other family members (parents and siblings).
Even if the lipid proﬁle is normal, close follow up with
lipid proﬁle is indicated. In our study, the second case was
screened at age one month and kept under close follow up.
When his triglyceride level was signiﬁcantly raised, lipid-
lowering agent was commenced. The family has a 2-year-old
girl who is on regular follow up for lipid proﬁle, and her
laboratory results are still within normal limits.4 Case Reports in Medicine
The most dramatic manifestation of FCS is acute pancre-
atitis.Itisresponsibleforupto7%ofallcasesofpancreatitis.
Failure to consider and investigate chylomicronemia as
a cause of pancreatitis may lead to an underestimation
of incidence. Hyperchylomicronemia-induced pancreatitis
rarely occurs unless triglyceride levels exceed 20mmo/L
(1760mg/dL). Acute pancreatitis, due to any cause, is
an emergency and necessitates an urgent intervention.
However, in patients with hyperchylomicronemia, further
management of hyperlipidemia to prevent future attacks is
recommended [17–19].
Early diagnosis is important to prevent complications
such as acute and chronic pancreatitis and pancreatic
necrosis, although pancreatic function often deteriorates
very slowly [3, 20]. Cardiovascular risk may also be increased
in these patients, though evidence has been inconclusive [3].
Unfortunately, FCS resulting from deﬁciency in LPL or apo
C-II is very diﬃcult to treat with existing pharmacologic
agents. The most eﬀective treatment modality is severe
dietary triglyceride restriction. The recommended targets
vary from less than 50g per day, or under 25% of total
daily caloric intake, to less than 20g per day, or under 15%
[2, 21, 22]. But a signiﬁcantly persistent high triglyceride
level necessitates pharmacological intervention. There has
been a general reluctance to use drug therapy to treat
lipid abnormalities in children; however, increasing evidence
suggests eﬀectiveness and short-term safety similar to those
in adults [23, 24]. Recently, the American Heart Associa-
tion provides general recommendations for pharmacological
management of high-risk lipid abnormalities in children and
adolescents. They deﬁned high-risk lipid abnormalities as
primary and secondary conditions associated with extreme
lipid abnormalities or conditions underlying high risk of
cardiovascular disease whereby the presence and severity of
lipid abnormalities may further exacerbate that risk [23].
The drugs studied and recommended for treating hyper-
tiglyceridemia are ﬁbric acid derivatives (e.g., Gemﬁbrozil,
Fenoﬁbrate). These have the eﬀect of both raising HDL
and lowering triglycerides. Main adverse eﬀects observed
were gastrointestinal upset together with an increased pre-
dispositiontocholelithiasis.Elevatedlivertransaminasesand
creatine kinase are transient. There is risk of myopathy and
rhabdomyolysis-especially if used with other agents, particu-
larly statins. Wheeler and colleagues performed a 6-month
randomized cross-over trial of Bezaﬁbrate in 14 children
with familial hypercholesterolemia [23, 25]. One patient had
transient elevation in liver transaminase and one patient had
elevation of alkaline phosphatase. The medication was well
tolerated with no impact on growth or development. Other
drugs, such as stains, were also studied and found to be
eﬀectiveintreatingfamilialhypercholesterolemiabutdidnot
have much eﬀect in lowering triglyceride level [23]. Niacin is
not recommended because of poor tolerance, serious adverse
eﬀects, and limited available data [1, 23, 26].
Both siblings in our study were started on Gemiﬁbrozil
300mg twice a day at birth and at age 6 months, respectively.
AA is now 7 years old and has had no attacks of acute
pancreatitis, although he was admitted twice with acute
gastroenteritis symptoms with suspicion of pancreatitis. He
has also had lipemia retinalis since birth due to very high
levels of triglyceride. Retinal evaluation after starting dietary
and drug therapy revealed improvement. SA is now 4 years
old and has never been admitted. There were no recorded
attacks of abdominal pain. His retinal examination remained
normal. Both children continue to tolerate Gemiﬁbrozil very
w e l l .T r i g l y c e r i d el e v e l sr a n g e db e t w e e n1 1a n d2 5m m o l / L
for AA and more than 16mmol/L for SA. Both children
have transient elevated liver transaminase, while alkaline
phosphatase remains within normal limits.
Ourstudynotedthatthehemoglobin(Hb)waslowwhen
the triglyceride level was high. This was initially noticed
whenAAwasﬁrstdiagnosed.HisHbwasverylowat6.7g/dL
(normal 13.6–19.6g/dL), with no evidence of hemolysis.
The Hb level improved with his improving triglyceride
level. This anomaly was also seen in SA, whose Hb, when
initially seen, was 18.7gm/dL and lipid proﬁle was mildly
elevated. Later, when he started to have signiﬁcantly raised
triglyceride levels the Hb continuously dropped. Recent tests
showed HB 10.9g/dL normal range (11.0–14.5g/dL) with
triglyceride level >16mmol/L (normal <1.70mmol/L). We
have no explanation for this observation.
We believe that this study is the ﬁrst to report FCS in
Saudi Arabia. A study was conducted in Saudi Arabia in 2001
for the prevalence of plasma lipid abnormalities in Saudi
children and concluded that the hypertriglyceridemia was
not seen as a major problem with only 1.96 % of the total
children felt to be in the high-risk group [27].
5. Conclusion
Familial chylomicronemia syndrome (FCS) is a disease of
late childhood and adolescence; however, cases have been
reportedininfantsandneonates.Thesyndromepresentation
is heterogeneous in a very young age group. Early diagnosis
and medical intervention by lipid-lowering agents and
dietary modiﬁcation, at the time of diagnosis, can improve
the prognosis and maintain a near normal lifestyle for
aﬀected children, as the risk of pancreatitis and frequency
of hospital admissions is signiﬁcantly reduced. Children
tolerate these agents well and show no serious side eﬀects.
Long-term studies are still needed to ensure the safety and
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